HCPCS C2624 is officially defined as "Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components." HCPCS C2624 is referenced in 9 tracked payer policy changes from Humana, Capital Blue Cross, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS C2624 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
This is a new Medicaid policy for Virginia establishing coverage criteria for various cardiac devices including automated external defibrillators, ICDs, wireless PAP sensors, and cardiac monitoring. The policy defines specific eligibility requirements and explicitly excludes coverage for cardiac contractility modulation systems and carotid sinus devices.
Capital Blue Cross added preauthorization requirements for Keytruda Qlex (J9999) and Grafapex (J0614), and for new aflibercept, denosumab, IVIG and ustekinumab products under J3590, Q5157, J1599 and Q5137, with the changes effective March 1, 2026. Policy updates effective February 1, 2026 and March 1, 2026 also removed preauthorization for procedure code 48556 for commercial plans and for procedure codes 64596 and 64598 for commercial plans, and for procedure codes 64570 and L8681 for Medicare Advantage.
Humana's Medicare Advantage policy on transcatheter and device-based hemodynamic procedures (policy HUM-1045-011) was revised with an effective date of 11/02/2026. The change summary lists this revision as an annual review with no coverage change, so the existing position carries forward: Humana states that implanted IVC and left atrial pressure monitors, and the subcutaneous heart failure decompensation monitor, are not medically reasonable and necessary. Carotid sinus baroreflex therapy has stated clinical criteria, and renal denervation and pulmonary artery pressure sensors follow CMS national coverage determinations 20.40 and 20.36.
Humana Virginia Medicaid updated its Cardiac Devices policy effective 2026-10-28, revising coverage criteria for implantable cardiac devices. The policy continues to cover cardioverter-defibrillators with leads, wireless pulmonary artery pressure sensors, and mobile cardiac outpatient telemetry under specific medical necessity criteria, while maintaining non-coverage of cardiac contractility modulation and carotid sinus baroreflex activation systems due to insufficient clinical evidence.
Humana Medicare Advantage updated its policy on transcatheter and device-based hemodynamic management procedures effective 08/03/2026. The policy clarifies coverage criteria for implantable carotid sinus baroreflex activation therapy (BAT) for heart failure, requires enrollment in approved IDE studies or strict clinical criteria including LVEF ≤35% and specific biomarker thresholds, and references CMS National Coverage Determinations for pulmonary artery pressure sensors and renal denervation procedures. All services must meet medical necessity standards and contraindication exclusions.
Effective June 15, 2026, heart failure management devices in the outpatient setting are considered investigational, including carotid baroreflex activation therapy (e.g., Barostim device), cardiac pressure sensor devices (e.g., CardioMEMS HF system and V-Lap), cardiac contractility modulation (CCM) devices (e.g., Optimizer Smart), and combined CCM with ICD devices (CCM-D) (e.g., Optimizer Integra CCM-D System). The February 19, 2026 annual review revised the policy statement to add baroreflex activation therapy devices as investigational, added a policy statement for CCM devices, added codes 0408T-0409T, 0915T-0916T and 0923T, and added code 64654 to replace code 0266T.
Humana Medicare Advantage has established new coverage criteria for implantable carotid sinus baroreflex activation therapy for heart failure and confirmed coverage follows CMS guidelines for pulmonary artery pressure sensors and renal denervation procedures. The policy excludes coverage for left atrial pressure monitoring and inferior vena cava hemodynamic monitoring devices.
Aetna considers validated home blood pressure monitors medically necessary as an alternative to ambulatory blood pressure monitoring to confirm hypertension in members age 18 and older with office readings greater than 140 systolic or 90 diastolic. Validated blood pressure monitors are considered medically necessary for members receiving hemodialysis or peritoneal dialysis in the home, and validated blood pressure cuffs are considered medically necessary durable medical equipment for members with hypertension. Self-contained pacemaker monitors, including audible and visible signal monitors, digital electronic monitors, and a specialized telephone attachment for trans-telephonic transmission of results, are considered medically necessary for members with cardiac pacemakers. Automated oscillometer serial blood pressure monitors for home use, AngelMed Guardian, CardioMEMS pillow and components, home and implantable congestive heart failure monitors, implantable inferior vena cava sensors, implantable wireless pulmonary artery pressure monitors for heart failure, Zoll Heart Failure and Arrhythmia Management System, bioelectrical impedance analysis, and non-invasive central blood pressure assessment with SphygmoCor are considered experimental, investigational, or unproven. Pulse tachometers do not meet Aetna's definition of covered durable medical equipment.
Aetna considers validated home blood pressure monitors medically necessary as an alternative to ambulatory blood pressure monitoring to confirm hypertension in members age 18 and older with office readings greater than 140 systolic or 90 diastolic, when the cuff is prescribed by a physician, is an arm device, has the correct cuff size assessed and provided by the vendor, and only one cuff per 5 years is considered medically necessary. Validated blood pressure monitors are also considered medically necessary for members receiving hemodialysis or peritoneal dialysis in the home, and self-contained pacemaker monitors are considered medically necessary for members with cardiac pacemakers. Pulse tachometers do not meet Aetna's definition of covered DME, and the following are considered experimental, investigational, or unproven: AngelMed Guardian, automated oscillometer serial blood pressure monitors for home use, bioelectrical impedance analysis, CardioMEMS, home congestive heart failure telemonitoring devices, implantable congestive heart failure monitors, the implantable inferior vena cava sensor, non-invasive central blood pressure assessment with the SphygmoCor System, and the Zoll Heart Failure and Arrhythmia Management System for monitoring pulmonary fluid levels. The bulletin is titled CPB 0548, reviewed 2025-08-22, with a last review of 08/21/2026.
Watch C2624
Get one email when a payer policy names C2624, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for C2624
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for C2624 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.